Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

ntrolled study of 446 patients at 44 international sites is designed to assess the TAXUS moderate-release paclitaxel-eluting coronary stent system in reducing restenosis in high-risk patients, including de novo lesions with overlapping stents, lesions 26 mm or greater in length and small vessels. Lesion size ranged from 18 - 40 mm in length and 2.5 - 3.75 mm in diameter. TAXUS VI is the first randomized, controlled clinical trial to demonstrate durability of drug-eluting stents in complex lesions at four years. Follow-up included 98 percent of the patients enrolled at four years.

The study's results demonstrate a continued significant reduction in target lesion revascularization (TLR, or retreatment rate) as compared to the bare-metal stent control group at four years. The four-year TLR rate was 12.9 percent for the TAXUS Stent group, as compared with 21.4 percent for the control group (P=0.0082 (only two TLR events were reported between three and four years for the TAXUS Stent group)). The rate of patients living free of TLR events was 87.1 percent at four years for the TAXUS Stent group, as compared to 78.6 percent for the bare-metal stent control group.

The four-year results for TAXUS VI support long-term safety with the increased levels of paclitaxel in the moderate-release formulation used in the study. Even with an in vitro dosing rate 8-10 times greater than the commercialized slow-release formulation, no compromise in safety was observed. The TAXUS Stent group continues to report no new stent thrombosis after two years with a low 2.4 percent cardiac death rate.

Boston Scientific launched the slow-release formulation TAXUS Express2 paclitaxel-eluting coronary stent system in Europe and other international markets in 2003 and in the United States in 2004. The Company launched the slow-release formulation TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system in Europe and other international markets in 2005. The TAXUS Express modera
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:5/28/2015)... , May 28, 2015  Transportation ... provider, announces winning the SDCE100 Award for ... & Demand Chain Executive magazine. Transportation ... consumer goods distributor quantify and control supply ... their highly competitive market. Deploying Transportation Insight,s ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... ) has announced the addition of Jain ... and Commercial Aspects"  to their offering.  ,     ... medicine or individualized treatment is to match ... and, in some cases, even to design ...
(Date:5/28/2015)... National Community Pharmacists Association (NCPA) CEO ... statement in response to a new report ... a number of generic drug costs increased substantially in ... previously expressed by NCPA and underscores the need for ... medications. Moreover, a 2015 survey of 700 community pharmacists ...
Breaking Medicine Technology:Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 2Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 3Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 4Global Personalized Medicine Report 2015-2024 - Scientific and Commercial Aspects 2Global Personalized Medicine Report 2015-2024 - Scientific and Commercial Aspects 3NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2
... BETHLEHEM, Pa., Nov. 14, 2011 MedClean Technologies, Inc. (OTC ... for the 2011 third quarter for the period ended September ... : The company has dramatically improved its ... the following key metrics, representing tangible progress: ...
... /PRNewswire-Asia-First Call/ -- American Oriental Bioengineering, Inc. (NYSE: ... company dedicated to improving health through the development, manufacture ... over the counter ("OTC") products, today announced that it ... call at 8:00 am EST on Tuesday, November 15, ...
Cached Medicine Technology:MedClean Technologies Announces Third Quarter Results 2MedClean Technologies Announces Third Quarter Results 3MedClean Technologies Announces Third Quarter Results 4MedClean Technologies Announces Third Quarter Results 5MedClean Technologies Announces Third Quarter Results 6MedClean Technologies Announces Third Quarter Results 7American Oriental Bioengineering to Hold Third Quarter 2011 Earnings Conference Call at 8:00 AM on November 15, 2011 2
(Date:5/28/2015)... May 28, 2015 Three years ago, Dr. ... for his Shore Vascular & Vein Center! Dr. ... system. It is his mission to provide the highest ... , Dr. Jeffrey Gosin is Board Certified in ... University of Pennsylvania and Jefferson Medical College. He completed a ...
(Date:5/28/2015)... Ross A. Clevens, MD, FACS, ... Teresa Beard as the new marketing director for Clevens ... oversee all marketing and promotional events for the practice. ... and developing compelling marketing strategies to achieve targeted results. ... served as guest communication manager at the Walt Disney ...
(Date:5/28/2015)... Boston Celtics Legend and Basketball Hall ... Foundation Board of Directors members, will be hosting their ... June 4-7. For the past 34 years, the Havlicek’s ... Foundation for children by bringing together friends, families, and ... John Havlicek Celebrity Fishing Tournament will be held from ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Senior Housing ... legend Lou Piniella, who managed the Seattle Mariners team ... Piniella will appear in television and digital advertising for ... living apartment communities, including several new communities slated to ... Bellevue, Bothell, Lynnwood, Mountlake Terrace, Tukwila, and University Place. ...
(Date:5/28/2015)... 2015 Healthpointe is proud to ... offering Echocardiography Examinations to patients with cardiovascular needs. ... Qualified Medical Examiner and licensed Cardiologist, Dr. Oscar ... a non-invasive and cost-effective approach to effectively diagnosing ... or have undergone surgery. Also known as ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:Clevens Face and Body Specialists Welcomes Teresa Beard as Marketing Director 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:SHAG Announces New Spokesperson: Lou Piniella 2Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2
... properties blocked bacteria formation, delayed onset of ... (HealthDay News) -- The use of silver-coated ... among intensive-care patients on ventilators, a U.S. ... lead to longer hospital stays, increased costs, ...
... In fact, new study hints they might be hazardous , , ... whether folic acid and vitamin B supplements help the heart ... any good and might have even caused participants harm. , ... -- no benefit of taking vitamin B supplements to reduce ...
... DIEGO, Aug. 19 NuVasive, Inc. (Nasdaq:,NUVA), a ... disruptive surgical treatments for the spine, announced today,that ... Sofamor Danek,alleging patent infringement involving certain NuVasive products., ... "It is not surprising,that Medtronic would attempt to ...
... India and BALTIMORE, Aug. 19 Lupin Ltd.,announced today ... marketing agreement for the AeroChamber Plus(R) line of products ... Lupin,Pharmaceuticals, Inc., USA, will use its 50 person sales ... is a Valved Holding Chamber (VHC) device that is,used ...
... COO, Former Experian Executive Will Lead Private Access, Mission to ... privacy management and ... clinical trials recruitment tools, ALISO VIEJO, Calif., Aug. ... enable management of detailed,privacy preferences for personal health information, announced ...
... MD, August 18, 2008Young researchers presented innovative, early-stage ... a collaborative project of the AUA Foundation and ... August 7-9, 2008. The AUA Foundation hosted the ... the most cutting-edge research in sexual medicine. ...
Cached Medicine News:Health News:Silver-Coated Ventilator Tubes Cut Risk of Pneumonia 2Health News:Vitamin B, Folate Supplements Won't Help Heart 2Health News:Vitamin B, Folate Supplements Won't Help Heart 3Health News:NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek 2Health News:NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek 3Health News:Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 3Health News:New research on sexual function 2